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ABSTRACT
Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used for 
therapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible. 
The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanism 
of action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for several 
conditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists can 
safely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offers 
exciting treatment options for dentists and patients in the future.
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INTRODUCTION
Botulinum toxin (BTX) is a deadly neurotoxin produced by Gram-
positive anaerobic bacterium called Clostridium botulinum. Ingestion of 
contaminated food (canned or preserved) or wound infection releases 
bacterial toxin into the blood stream, eventually leading to severe 
symptoms of botulism such as vomiting, slurred speech, respiratory 
arrest, paralysis, and even death [1,2]. Botulinum, a natural protein and 
lethal neurotoxin is one of the most potent biological substances known 
which is used in bioterrorism as well [3]. It is the first toxin used for 
therapeutic purposes.
Justinus Kerner (1786-1862) gave the first complete description of 
clinical botulism, a life-threatening disease and called the toxin a 
“sausage poison,” because it was observed that illness occurred after 
ingestion of spoiled sausage. In 1870, John Muller coined the term 
“botulism” (which means “sausage”). In 1949, Burgern was the first to 
discover that the toxin was able to block neuromuscular transmission. 
There are seven different toxin serotypes, namely, A, B, C, D, E, F and 
G, which differ in their potency, duration of action, and cellular target 
sites [4]. In human beings, botulism is mainly caused by types A, 
B, E, and rarely F, whereas in animals it is caused by types C and D. 
Commercially available variants are BTX-A and BTX-B, where BTX-A is 
the most commonly used toxin in medicine and dentistry. BTX-B is used 
in cases of resistance to BTX-A. BTX-E and BTX-F are used only for those 
individuals who do not respond to A and B due to clinical resistance 
or antibody formation. BTX-A is marketed worldwide under the name 
Botox (onabotulinum toxin A), Dysport in Europe, Xeomin in Germany, 
and Prosigne in China. BTX-B is marketed as Myobloc in the USA and 
Neurobloc in Europe.
Since 1989, BTX has been used for medical treatments but has 
recently become a popular innovative dental treatment option. Botox 
was approved by the US Food and Drug Administration (FDA) for the 
treatment of strabismus, blepharospasm, hemifacial spasm, facial 
glabellar lines, cervical dystonia, and axillary hyperhidrosis [5]. BTX-B 
has been approved by the FDA for the treatment of cervical dystonia. 
Since then BTX-A has been used for the treatment of various disorders 
in the orofacial region [6].
CHEMICAL STRUCTURE
BTX is synthesized as a single chain (150 kDa) and subsequently 
cleaved by host proteolytic enzymes into a di-chain molecule consisting 
of a 100 kDa binding subunit and a 50 kDa toxic subunit linked by a 
disulphide bond (Fig. 1). The light chain acts as a zinc endopeptidase 
with proteolytic activity located at the N-terminal end. The heavy 
chain provides cholinergic specificity and binding of the toxin to 
presynaptic receptors. This promotes translocation of the toxin across 
the endosomal membrane [7].
PREPARATION OF BTX
BTX is prepared by laboratory fermentation of the bacteria C. botulinum, 
which lyses and liberates the toxin into the culture. The toxin is then 
harvested, purified, crystallized with ammonium sulfate, diluted with 
human serum albumin, lyophilized, bottled in vials (sterile, vaccum 
dried powder form), and sealed for single use. Optimal pH of the solution 
is between 4.2 and 6.8, and vials should be stored in a freezer at or 
below −5°C. Preparations should be reconstituted with 1-5 mL of saline 
without preservatives just before use. Because Botox is easily denatured 
via bubbling or agitation, the diluent should be gently injected onto 
the inside of the wall of the vial. The reconstituted solution should be 
refrigerated at 2-8°C and used within 4 h. The preferred syringe for 
injection is a 1.0 mL tuberculin syringe with a gauge of 26-30 [8].
The potency of BTX is expressed as mouse units, with 1 mouse unit 
equivalent to the median lethal dose (LD 50) for a colony of 20 g Swiss 
Webster mice. Botox is dispensed in vials containing 100 U, while 
Dysport in vials containing 500 U. The relative potency of Botox units 
to Dysport units is approximately 1:4. BTX-B (Myobloc/Neurobloc) is 
available in vials of 2500 U/0.5 mL, 5000 U/mL, or 10,000 U/2.0 mL. 
Its relative potency to Botox is 50-125 U of Myobloc to 1 U of Botox. 
This product does not require reconstitution and is stable for up to 
21 months in a refrigerator. Botox produces dose-dependant paralysis. 
When compared with BTX-B, BTX-A causes less pain during injection, 
longer duration of action, and more predictable diffusion patterns. The 
usual maximum total recommended therapeutic dose at an injection 
session in the dental office is about 80-100 U. Cosmetic dosages are less 
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BTX injections are accomplished via a single-point or a skewered 
method with the needle inserted parallel to the plane of the muscle, 
and the injection is performed while the needle is carefully withdrawn. 
Care should be taken to space injections about 1-2 cm apart and to 
avoid injecting into muscles where paralysis is not desired [9]. BTX 
diffuses up to 10 mm into the adjoining areas, so a thorough knowledge 
of related anatomy is necessary to prevent undesirable effects. Gently 
pinching the muscle during injection may help reduce pain and ensure 
superficial placement of the drug. Topical anesthetic or ice may also be 
used to reduce pain during injection. Pressure with gauze immediately 
after injection is advisable to prevent bleeding and bruising and 
massaging the area after the injection is not recommended to prevent 
the unwanted diffusion of the toxin into adjacent muscles [10]. 
Strenuous physical activity should be avoided for 1 day after treatment. 
Injections are spaced out for a minimum of 3 months to minimize the 
risk of antibody formation to the protein, which would prevent BTX 
from working the subsequent time. Injections can administered with 
the help of electromyography (EMG) or ultrasound guidance for deeper 
muscles and joints. Topical formulations of BTX-A are also used for 
treating axillary hyperhidrosis with promising results.
MECHANISM OF ACTION
In the blood, the toxin targets peripheral neurons of the central 
nervous system (CNS) and binds to ganglioside receptors on the 
neuronal surface via the large subunit. Changes in pH at the neuronal 
surface mediate penetration of the membrane and passage of the small 
subunit into the neuron. The small subunit of the protein possesses a Fig. 1: Chemical structure of botulinum toxin
Fig. 2: Mechanism of action of botulinum toxin
than the therapeutic dose. The human lethal dose is estimated to be 
approximately 3000 U. Thus, clinical dose can be given safely without a 
fatal overdose complication. The treatment dose varies for each brand 
of toxin and different parts of the body.
ADMINISTRATION OF BTX
It is injected either intramuscular, intradermal, intraglandular or into the 
affected area depending on the condition to be treated. Intramuscular 
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metalloprotease activity which cleaves components of the neuronal 
SNARE complex (Fig. 2). This complex is implicated in releasing 
neurotransmitter, acetylcholine when released depolarizes the motor 
end plates of the muscle thereby causing muscle contraction. Inhibition 
of this release leads to abolition of stimulatory activity of the neuron. 
This lack of stimulatory activity can cause paralysis, a major side effect 
of BTX administration.
Thus, BTX inhibits the release of acetylcholine from the presynaptic 
nerve terminal effectively and will either reduce the intensity of the 
contraction of the muscle or will eliminate the contraction altogether, 
depending on the dosage used. Thus, Botox causes a temporary muscle 
paralysis which lasts up to 3 months. Gradually, the muscle returns 
to its full function with no side effects as the muscle initiates new 
acetylcholine receptors, and the growth of branches from the neurons 
to form new synaptic contacts [11]. The toxin has also been shown to 
block acetylcholine release at parasympathetic nerve terminals. The 
clinical effects appear between 1 and 3 days after administration of BTX, 
and the maximum effects occur after 1-2 weeks, which then stabilizes to 
a moderate level until complete recovery of the nerve in approximately 
3 months [12]. BTX does not inhibit the production of acetylcholine, 
and therefore, motor function is recovered by subsequent motor axon 
outgrowth [13].
Repeated treatments and increasing dosage with Botox have been 
shown to cause atrophy of the underlying muscles, usually leading to 
longer resolution of the problem. The antinociceptive and analgesic 
properties of BTX-A are also much discussed in the literature and have 
suggested that the BTX-A can play an independent role in peripheral 
nociceptors by blocking the release of certain neurotransmitters such 
as substance P, glutamate, and calcitonin gene-related peptide [14]. 
Resistance is most likely associated with increased doses and frequency 
of treatment sessions [15,16]. Repeat doses of 300 U and above have 
been associated with resistance [17]. Hence, treatment should be 
started with the minimal dose required and can be gradually increased. 
Injections are spaced out for a minimum of 3 months to minimize the 
risk of antibody formation to the protein, which would prevent Botox 
from working the subsequent time. The use of other serotypes (F or B) 
may benefit those who have devolved antibody resistance [18].
CLINICAL APPLICATIONS OF BTX IN THE OROFACIAL REGION
Cosmetic applications
Facial wrinkles occur naturally with due to pull off the skin by the 
underlying musculature, but becomes more prominent with aging 
and are unesthetic [19]. Botox has been approved for treating these 
hyperfunctional facial lines. When injected, it weakens the underlying 
muscles and is used worldwide successfully for treating glabellar 
(frown) lines, frontalis and lateral canthal lines (crow’s feet), platysma 
bands, perioral lines, mentalis wrinkling, lower eyelid orbicularis 
hypertrophy, and vertical lip rhytids (lipstick lines) [20,21]. It is also 
used to treat hypertrophic scars and keloid with good results. Botox 
used in conjunction with dermal fillers have proved to be very beneficial 
for the correction of facial wrinkles [22,23]. BTX-A and dermal fillers 
have been used to provide immediate volume to black triangles formed 
due to loss or inadequate interpapillary tissue in the oral cavity [24,25].
Therapeutic applications
Gummy smile
The gummy smile is characterized by a marked gingival exposure on 
smiling of more than 3 mm. In the gummy smile caused by muscle 
hyperfunction, the BTX is injected into the lip elevator muscles thereby 
causing paralysis of them and resulting in less gingival display. It 
is the first preferred method in such cases due to ease and safety of 
applications, rapid effect, and more conservative method compared 
to surgical procedures (myectomy or Le Fort I osteotomy). Irineu 
presented a case of gummy smile successfully treated with BTX and 
showed that better results could be obtained with BTX either alone or as 
an adjuvant therapy to gingival resection surgery [26]. Several authors 
have demonstrated that BTX-A injections can be used successfully for 
treating gummy smiles [27-32].
Temporomandibular disorders (TMD)
TMD is a term which includes not only disorders of the 
temporomandibular joint (TMJ) but also includes a wide range of 
disturbances associated with the function of the masticatory system. 
TMDs may be myofascial (those related to muscles themselves) or 
arthrogenic (those related to TMJ) or both of them, but the majority 
of TMDs include a myogenic component, in which hyperactivity of the 
masticatory muscles are present [33]. Hence by directing treatment at 
the muscular component of TMD, therapeutic gains can be achieved. 
TMD symptoms can include jaw pain, neck pain, facial pain, difficulty 
with jaw opening, earaches, headaches, pain behind the eyes, jaw 
joint popping and clicking, dizziness, and difficulty chewing food or 
occluding the teeth. TMD are considered the major cause of pain in 
the orofacial region [34]. It has been shown that BTX injections can 
be the least invasive mode, which can provide relief of intractable 
symptoms in patients who have failed to show any improvement with 
the conventional modalities of treatment [35,36]. Injecting measured 
doses of BTX into specific sites (3-5 sites/muscle) in the major 
muscles of mastication can achieve sufficient masticatory muscle 
relaxation [37,38]. Although no definite protocol has been proposed, 
various case reports have recorded significantly decreased pain, and 
improved function and mouth opening at doses ranging from 25 to 
150 U of Botox injected intramuscularly into temporalis and masseter 
muscles for treating TMD [39].
In a study conducted by Freund et al. on 46 patients suffering from 
TMD, it was found that with150 U injections of BTX to the temporalis 
and masseter muscles; there was a remarkable improvement in mouth 
opening as there was a reduction in pain over masticatory muscles [40]. 
Lee et al. evaluated the effect of BTX injections on pain in six patients 
with limited mouth opening due to TMD. In all of their patient’s 
symptoms subsided without any adverse effects during the 5-12 months 
follow-up period [41]. BTX injections have been used effectively for the 
treatment of masticatory muscle hypertonicity and parafunction [42]. 
The treatment protocol according to Katz included one injection of BTX 
7.5 U bilaterally into the anterior fibers of each temporalis muscle, and 
additional injections of 2.5 U are given into the middle and posterior 
third of the temporalis muscles in the most severe cases. Masseter 
muscle is treated with 5 U injections. [42]. Zhang et al. in their study 
concluded that BTX-A has obvious advantages for the treatment of TMD 
in terms of reducing the occlusal forces, but psychological intervention 
plays an important part of the treatment [43]. Park et al. found that 
Masseter muscle activity as measured by EMG was immediately 
decreased after a BTX-A injection [44]. There is strong evidence that 
BTX is a valuable clinical tool in the management of the myofascial 
component of temporomandibular disorders. The temporalis and 
masseter muscles are always treated bilater ally even if only one side of 
the face is involved.
Bruxism
Bruxism refers to both clenching and grinding of the teeth. Etiology is 
multifactorial and has a psychologic component involved. Bruxism can 
affect both TMJ and masticatory muscles. Bruxism destroys healthy 
dentition, exacerbates periodontal disease, causes TMD and ultimately 
leading to headaches and facial pain. Patients with chronic bruxism 
can have difficulty in speaking, chewing, swallowing and restricted 
mouth opening. BTX-A injections have been used to treat patients with 
parafunctional habits like bruxism by injecting into the flexor muscles 
of mandible which resulted in the relaxation of muscles in most of the 
cases. Bilateral injections of BTX-A in the dose range of 25-100 U per side 
into the masseter and temporalis muscles have provided resolutions 
of the symptoms of bruxism. BTX-A injections by removing bruxism 
element reduce facial pain, TMD symptoms and can significantly help 
the other associated treatments of periodontal disease [45]. This has 
also been proven useful in sleep bruxism [46,47].
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Van Zandijcke and Marchau [48] described the successful treatment 
of a brain-injured patient with severe bruxism with 100 U of BTX-A 
injections to the temporalis and masseter muscles and reported marked 
reduction in bruxism during the recovery period from coma. Tan and 
Jankovic [49] treated 18 patients with a history of severe bruxism by 
injecting BTX into the masseter muscle with mean dose of 61.7 U/side 
(range 25-100 U) and obtained a total duration of therapeutic response 
of 19 weeks. Maaytah et al. [50] reported that BTX injection in the 
masseter muscles is an effective and safe means of intervention in 
cases of severe post-traumatic bruxism. It may be the only practical 
intervention available during the period of severe bruxism seen after 
brain injury when the patient is unable to cooperate. Ivanhoe et al. 
reported success with a 200 U dose of BTX-A for severe bruxism in a 
patient with brain injury [51].
Masseter muscle hypertrophy
It is the unilateral or bilateral enlargement of the masseter muscles, 
which is mostly associated with clenching and bruxism. Other causes 
are anatomical asymmetry of the jaw, habitual asymmetric use of the 
jaw, or congenital malformations. This condition is commonly treated 
with Botox injections into masseter muscle [52], which thins the 
muscle and reduces the intensity of contraction of masseter muscle 
unlike surgical excision in which muscle bulk is reduced permanently. 
Recurrence of this condition is common in 6 months with BTX, as 
it reduces muscle volume only temporarily thereby making repeat 
injections necessary [53]. In a clinical trial, the injection of 30 U 
per side of BTX into the masseter muscles resulted in a sustained 
reduction of gross masseter size (maximum reduction 35.4%) [54]. 
Various clinical trials [55-57] reported that injections of BTX into 
the masseter muscles resulted in a sustained reduction of masseter 
hyperactivity. With BTX-A injections good, facial contour was 
achieved [58,59] and several cases were treated successfully [60]. 
Similarly, temporalis muscle hypertrophy can be treated with BTX 
injections [61].
Myofascial pain
TMD are considered a subgroup of musculoskeletal and rheumatologic 
disorders and represent the main cause of nondental pain in the orofacial 
region. For facial pain and TMD cases, BTX-A can be generally applied 
to a number of muscles of facial expression and mastication [62]. The 
FDA has approved BTX-A as a primary treatment for migraine and facial 
pain using a treatment protocol involving the muscles. BTX-A injections 
resulted in relief of pain in facial muscles in 90 percent of patients 
who did not respond to traditional treatments [63]. EMG evaluations 
were also used to evaluate the effects of BTX-A on muscle activity of 
patients with myofascial pain, with or without disc displacement. The 
results showed a decrease of muscle potential action of the masseter 
in the evaluation after 14 days and an increase in potential 28 days 
after the procedure. It was also found that the reduction of pain and 
improvement in psychological indices persisted at reassessment 
28 days after the intervention [64].
BTX appears relatively safe and effective in treating cervical 
dystonia and chronic facial pain associated with masticatory 
hyperactivity [65]. Several studies have shown BTX-A injections to 
be effective in cases of chronic facial pain associated with muscle 
hyperactivity/bruxism [66-68]. Machado et al. [69], in their study, 
concluded further randomized controlled clinical trials, with 
representative samples and longer follow-up time, are required to 
assess the real effectiveness of BTX injections in the management of 
masticatory myofascial pain and muscular TMD. Injection of muscles 
with Botox has been reported to be effective for myofascial pain 
caused by trigger points [70]. Research has certainly shown that 
Botox and Dysport achieve successful treatment for many facial, TMD 
and oral dysfunctions which originate from the musculature [71]. 
Sidebottom et al. in their prospective study concluded that BTX is a 
valuable alternative second line treatment for masticatory myofascial 
pain when conservative measures have failed [72].
Mandibular spasm
It is a condition in which the elevator muscles of mandible are in a 
spasmatic condition resulting in restriction of mouth opening and pain 
during mandibular movements. Intramuscular Botox injections have 
resulted in relaxation of muscles, reducing inflammation of muscles 
and TMJ and the guarding response to pain thereby improving mouth 
opening. Several case reports have been published [73-76] describing 
the effectiveness of BTX-A in patients with hemimasticatory spasm, 
where all the patients responded positively to intramuscular Botox 
injections.
Oromandibular dystonia (OMD)
OMD is characterized by involuntary contraction of the masticatory 
and lower facial muscles causing unintentional opening and closing of 
the mouth in vertical, lateral, and protrusive directions. This will also 
result involuntarily chewing of the soft tissue inside the mouth often 
interfering with regular chewing and speaking. Although there is no 
cure for OMD, BTX injections have been the mainstay of treatment for 
most focal dystonia. Denervation of motor endplates has been proposed 
as the leading mechanism of action of BTX in dystonia, including OMD. 
Masseteric injection of Botox has been used for OMD as well as for 
plethora spasm which is often related conditions [77]. Literature on 
OMD treatment has reported improvement of symptoms with the use of 
BTX injections [78-82]. Over a 10-year period, Tan and Jankovic treated 
162 patients with OMD by injecting BTX-A into the masseter muscles 
and/or the sub-mentalis complex, and improvement in chewing and 
speaking was reported in 67.9% of the patients [79].
TMJ dislocation
Recurrent dislocation of TMJ can occur due to OMD, epilepsy, stroke, 
and dyskinesias. BTX injection is specially indicated in patients in which 
conservative treatment has failed and surgery carries major risks. 
BTX-A has been used to treat recurrent TMJ dislocation by injecting 
into lateral pterygoid muscle in most of the cases and masseter muscle 
in some of the cases [83-86]. Bhogal et al. [87], in their review article, 
stated that mandibular dislocation when treated with BTX injection into 
lateral pterygoid muscles; the results lasted for a minimum of 3 months. 
Intramuscular BTX injection in lateral pterygoid muscle as an adjunct to 
arthrocentesis in the treatment of internal derangement of TMJ gave a 




Excessive saliva production or the inability to hold saliva in the 
mouth can result in sialorrhea or drooling. Xerostomia is one of the 
manifestations of botulism, which led to the introduction of BTX to 
treat sialorrhea and drooling. BTX-A treated for sialorrhea associated 
with Parkinson’s disease had a very favorable outcome when injected 
into parotids or both parotid and submandibular glands to inhibit the 
stimulation of cholinergic receptors [89-92]. Fuster et al. injected BTX 
into parotid submandibular gland or both with doses varying from 10 
TO 100 units, which resulted in reduction in saliva production which 
lasted for 6 months [93]. This has to be done carefully, as too much 
will result in chewing difficulties, dysphagia and xerostomia. Botox is 
administered mostly only into parotid gland in a dose range of 30-70 U 
with a significant reduction in salivary flow observed in a month. 
However, the effects last only up to 3 months, and repeat injections are 
often necessary. BTX-A also had been treated with success for sialorrhea 
in patients with amyotrophic lateral sclerosis, cerebral palsy, and other 
neurological disorders which are caused by muscarinic type cholinergic 
hyperactivity [94-97].
It has also been used successfully in patients with post-traumatic and 
iatrogenic salivary sialoceles [98] and acute postparotidectomy salivary 
fistula [99]. Botox is useful in cases of drooling or salivary fistulas after 
oropharyngeal cancer surgery where temporary stopping of glandular 
secretory action is needed to promote healing [100]. Bartolo corradino 
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et al. [101], in their study, injected 80-100 U of BTX -A preoperatively 
into major salivary glands for 43 oral cancer patients who underwent 
surgery and found that there was a considerable, temporary reduction 
of salivary secretion thereby avoiding the postoperative complications 
due to saliva stagnation and also helped in better healing and outcome 
of the surgery.
Frey’s syndrome
Other uses of BTX are to treat auriculotemporal (Frey’s) syndrome. 
However, its transient effectiveness (3-4 months) requires multiple 
injections. Intradermal injection of BTX into the affected area resulted 
in greater improvements in patients suffering from gustatory sweating, 
and the effects were long-lasting than intramuscular injections. [102]. 
Laccourreye et al., in a follow-up study of 33 Frey’s syndrome patients 
treated with BTX, found recurrence rates of 27% in the 1st year, 63% in 
the second, and 92% in the 3rd year [103]. Guntinas-Lichius in his study 
demonstrated that using a higher concentration of BTX is more effective 
than a lower concentration in the treatment of Frey’s syndrome [104]. 
Several other studies have also confirmed that BT is safe and efficacious 
treatment for gustatory sweating [105,106].
Facial nerve palsy
Facial nerve palsy is a disfiguring condition for the patient and has 
been treated successfully with BTX. In patients with facial asymmetry, 
BTX injections into the normal side have been reported to result in 
an apparent symmetrical function of the face [107-109]. BTX-A is 
commonly used to treat facial synkinesis with marked improvement 
of facial symmetry at rest and during voluntary movements [110,111]. 
Hyperlacrimation (crocodile tears) which may occur after a facial palsy 
has been successfully treated by injecting BTX into lacrimal glands [112]. 
It has also been used to intentionally induce ptosis to protect cornea in 
facial palsy patients by injecting into the levator palpebrae superioris 
muscle [113]. There are also reports of BTX injections into lateral rectus 
and medial rectus muscles for treating third and sixth cranial nerve 
palsies with varied improvements.
Pain in head and neck region
BTX-A was found very effective in the management of various facial 
pain conditions such as tension headache, migraine, myofascial pain, 
trigeminal neuralgia and in post-operative wound pain including TMJ 
surgery, blowout fracture repair and reconstructive facial surgery. 
Botox 25-75 U injected into pericranial muscles relieves a headache 
by relaxing the overactive muscles by blocking nerve impulses that 
trigger contractions. For migraines Botox works by blocking the 
protein that carries the message of pain to the brain and relief typically 
takes effect in 2-3 weeks after injection and the longer the treatment 
duration, the better the pain relief [114]. Jennifer Warner reported pain 
relief in 25 patients with chronic neck pain after a single injection of 
Botox delivered to the affected neck muscle combined with standard 
physiotherapy [115]. BTX inhibits substance P and is used in relieving 
excruciating pain associated with inflammation of trigeminal nerve, as it 
is an anti-inflammatory agent. Analgesic effect following BTX injections 
in orofacial pain are due to direct analgesic and neuromodulating 
mechanisms of BTX in the CNS, anti-inflammatory effects, and effects on 
the myofascial tender point [116]. Botox is also very useful in treating 
chronic pain syndrome [117]. Another study reported that BTX causes 
normalization of increased muscle spindle activity, decompression of 
afferent nociceptive neurons of muscular and vascular tissue [118].
Trigeminal neuralgia
Trigeminal neuralgia is frequently confused with dental pain and needs 
to be considered more often as a possible diagnosis when all other 
dental and muscle pathologies have been eliminated as the source of 
dental and facial pain. BTX-A use is increasing for trigeminal neuralgia 
cases and while the mechanism of action has not been well established, 
it has been a useful adjunct to treating these patients as primary or 
secondary treatment [119-121]. Ngeow and Nair described a persistent 
case of trigeminal neuralgia, when treated with 100 U BTX-A injection 
responded well immediately and the patient was completely relieved 
of pain for 5 months. Pain recurred later for which BTX injection was 
repeated and underwent neurosurgery after 1 year [122].
Other uses
Oral and maxillofacial trauma
In the treatment of various facial bone injuries, such as condylar, zygoma 
fractures, and BTX injections has proven to be useful in assisting post-
operative wound healing by weakening/relaxing muscles, thereby 
reducing displacing forces on the fracture ends and obtain good 
immobilization if rigid fixation is not possible [123-126]. It also helps in 
reducing the number of plates required for stabilizing the bones. Facial 
laceration wound healing was better with BTX [127,128].
Implantology
Parafunctional habits like bruxism or stress due to any excessive 
functional forces during osseointegration stage of implants can cause 
implant failure. Application of BTX relaxes masticatory muscles 
and helps in unimpeded osseointegration of implants especially in 
immediate load implant protocols [129]. However, not many studies 
demonstrate the beneficial effects of BTX use in dental implantology. 
Further randomized controlled trials are needed to evaluate their use 
in dental implantology [130]. Relapse is a problem after orthodontic 
treatment and/or orthognathic surgery and the root cause are the 
hyperactive muscles, e.g., mentalis muscle. BTX-A can reduce muscle 
contraction intensity, and over time, muscles can be trained to work 
normally. Similarly, in a patient receiving complete dentures BTX 
injections into muscles such as masseter, medial, and lateral pterygoid 
can be done for muscle training, thus enhancing in gradual adaptation 
of the orofacial musculature to the denture. In addition, according to 
Seok et al., the injection of BTX-A into the digastric muscle corrected 
the post-traumatic anterior open bite [131]. Chow et al. used BTX-A 
injections for treating ranula in 3 patients and achieved good 
results [132].
Contraindications
There are no absolute contraindications for BTX use. Relative 
contraindications include pregnancy, lactation, neuromuscular 
diseases (e.g., myasthenia gravis, amyotropic lateral sclerosis, Eaton-
Lambert syndrome, and Charcot disease), motor neuron disease, drug 
interactions (aminoglycosides, muscle relaxants, quinidine, calcium 
channel blockers, magnesium sulfate and polymyxin), allergy to 
any of the components of BTX-A or BTX-B (i.e. BTX, human albumin, 
saline, lactose, and sodium succinate), infection at injection site and 
psychologically unstable patients.
Complications
Local side effects are mild and include Pain, edema, headache, 
erythema, ecchymosis, blepharoptosis, and perioral muscular palsy. 
Other complications during therapeutic applications are dry eyes, 
mouth droop, lid edema, xerostomia, transient dysphagia, trismus, 
nasal regurgitation, nasal speech, blurred vision, dizziness, upset 
stomach, infection, neck weakness, voice changes, difficulty in chewing 
and breathing, risk of aspiration, recurrent jaw dislocation, dysarthria, 
salivary duct calculi, injury to branches of the facial nerve, facial muscle 
weakness, and facial asymmetry during movements. Systemic side 
effects are nausea, fatigue, headache, facial pain, flu-like symptoms, 
anxiety, itching, and transient weakness [1].
According to Cote et al. [133] in 2005, the adverse event reported to 
the FDA (1989-2003) after therapeutic and cosmetic use of BTX was 
1437 cases. 217 serious adverse events were reported including 
28 reported deaths; respiratory arrest, myocardial infarction, 
cerebrovascular accident, pulmonary embolism, and others [21]. All 
of them were related to therapeutic application rather than cosmetic 
purpose of the BTX. FDA issued a Black Box warning in 2009 because of 
the ability of BTX to migrate from injection site (systemic toxicity), that 
could lead to life-threatening symptoms of botulism (dysphagia and 
breathing difficulties) which is more likely to occur after intramuscular 
injections even with therapeutic doses. Botulism-like symptoms are 
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muscle weakness, hoarseness or dysphonia, dysarthria, loss of bladder 
control, difficulty breathing, difficulty swallowing, double or blurred 
vision, and drooping eyelids which can occur anywhere from a day 
to several weeks after treatment at unrelated sites. However, safety 
of BTX-A in clinical uses has been well established [134]. Most of 
the adverse effects are linked to local tissue diffusion of BTX. Careful 
attention to drug dose, dilution, handling, storage, and site of injection 
are required for optimal treatment outcome and to minimize adverse 
effects.
SUMMARY
BTX is increasingly being used in medicine and dentistry and is 
associated with a few reversible adverse effects [128]. It is used in 
the field of oral and maxillofacial surgery for more than two decades. 
Botox applications are expanding in the treatment of various 
orofacial disorders. Its applications range from cosmetic to various 
therapeutic purposes such as temporomandibular disorders, salivary 
secretory disorders, hyperhidrosis, facial paralysis, orofacial pain, and 
implantology [135-139]. Even though numerous publications have 
reported successful outcomes after BTX application, they are mostly 
case reports and case series. There are only a few scientific reports 
with the high level of scientific evidence. Hence, more good quality 
clinical research needs to be carried out with randomized, controlled, 
blinded settings to understand the properties, clinical efficacy, and 
any associated long-term adverse effects. Treatment with BTX cannot 
be considered curative but a simple, safe, palliative, and symptomatic 
approach to the management of a problem. BTX treatments have shown 
to have a low risk of side effects and contraindications, are comparably 
cost effective, reversible and relatively safe, which makes this treatment 
choice popular among patients and dentists.
Dentists are highly knowledgeable regarding oral and facial anatomy, 
which seems reasonable for them to be at the forefront in providing 
these services, understanding limitations of treatment and having the 
ability to recognize and manage complications. As Botox treatment 
is technique, sensitive appropriate training is essential not only to 
administer the drug but also to deal with potential adverse effects. 
Benninger et al. [140] concluded from their study that BTX-A is an 
effective treatment for oral pathologies and dentists should be allowed 
to inject BTX-A based on their didactic and clinical anatomy courses 
and clinical curriculum. This study revealed the training of a general 
dentist appears to satisfy the basic science knowledge and clinical 
skills one would need to administer BTX-A injections to the head and 
neck region. Dentists worldwide are now treating patients with BTX-A 
for various oral and maxillofacial aesthetic and therapeutic purposes, 
and Botox injections are being integrated into dental treatment plans 
routinely [141,142]. But according to Al Hamdam et al., dentists in 
Saudi Arabia were hesitant in using BTX injections and derma fillers 
as they were lacking in knowledge and confidence regarding BTX 
injections and were worried about complications of BTX injections, 
which emphasizes the need for adequate training programs regarding 
BTX injections for the dentists [143].
CONCLUSION
BTX treatment is relatively safe and efficacious, less invasive, 
conservative and the effects are faster and reversible. It is used 
for both cosmetic and therapeutic purposes. The role of BTX as a 
therapeutic agent for several conditions is expanding. With training of 
BTX-A injection techniques and adequate knowledge about treatment 
protocols, general dentists can safely administer BTX injections. The 
ability to use Botox as an adjuvant and primary mode of treatment for 
various maxillofacial disorders offers exciting treatment options for 
dentists and patients in the future.
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